Rosvamac F Tablets

Description: Rosvamac F Tablets contain Rosuvastatin and Fenofibrate which are synthetic lipid-altering agents. Pharmaceutical Dosage Form: Tablet Route of Administration: Oral Composition:

Mechanism of Action: Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of Rosuvastatin is the liver, the target organ for cholesterol lowering. Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles. Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type alpha (PPARα). Through activation of PPARα, fenofibrate increases the lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apo protein CIII. Activation of PPARα also induces an increase in the synthesis of Apo proteins AI and AII. The above stated effects of fenofibrate on lipoproteins lead to a reduction in very low- and low-density fractions (VLDL and LDL) containing Apo protein B and an increase in the high-density lipoprotein fraction (HDL) containing Apo protein AI and AII. Indications: Rosvamac F Tablets are indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, non-HDL-C, and TG and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia, Familial Hypercholesterolemia, Hypertriglyceridemia, Primary Dysbetalipoproteinemia, Homozygous Familial Hypercholesterolemia, slow the progression of atherosclerosis, Prevention of Cardiovascular Disease Dosage: As directed by the physician. Storage: Store at a temperature not exceeding 25°C, protected from light & moisture. Presentation: 10 X 10 Tablets Side effects: Headache Dizziness Constipation Nausea Abdominal Pain Myalgia Asthenia Contraindications: Rosvamac F Tablets are contraindicated in patients with a known hypersensitivity to any component of this product, active liver disease, severe renal dysfunction, including those receiving dialysis, myopathy, receiving concomitant ciclosporin, receiving concomitant combination of sofosbuvir/velpatasvir/voxilaprevir, pre-existing gallbladder disease, pregnancy and nursing mothers. Drug Interactions: Rosvamac F Tablets can cause drug interaction with following drugs: Transporter protein inhibitors Ciclosporin Protease inhibitors Gemfibrozil and other lipid-lowering products Ezetimibe Antacid Erythromycin Cytochrome P450 enzymes Glitziness